Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.88 |
| ▸ | EYA2 | O00167 | 1/20 | 0.88 |
| ▸ | APP | P05067 | 1/20 | 0.88 |
| ▸ | ACE | P12821 | 1/20 | 0.88 |
| ▸ | BLM | P54132 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL42175 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1566615 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL531145 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL121502 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL531146 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL4533309 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Pentetic Acid SCHEMBL2819134 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2327395 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8331922 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5571235 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414490-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2023-12-28 | — | — | US | claimed |
| US-20220023200-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2022-01-27 | — | — | US | claimed |
| US-20190314365-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2019-10-17 | — | — | US | claimed |
| US-10376505-B2 | Oral formulations and lipophilic salts of methylnaltrexone | WYETH, LLC (US) | 2019-08-13 | — | — | US | claimed |
| US-10357449-B2 | — | — | 2019-07-23 | — | — | US | claimed |
| US-10307417-B2 | Oral formulations and lipophilic salts of methylnaltrexone | WYETH, LLC (US) | 2019-06-04 | — | — | US | claimed |
| US-20190117645-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2019-04-25 | — | — | US | claimed |
| US-20190117646-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2019-04-25 | — | — | US | claimed |
| US-9724343-B2 | Peripheral opioid receptor antagonists and uses thereof | WYETH, LLC (US) | 2017-08-08 | — | — | US | claimed |
| EP-3178472-A1 | ORAL FORMULATIONS OF METHYLNALTREXONE | Wyeth LLC (US) | 2017-06-14 | — | — | EP | claimed |
| US-20140249171-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2014-09-04 | — | — | US | claimed |
| US-20130330407-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2013-12-12 | — | — | US | claimed |
| US-8524276-B2 | Oral formulations and lipophilic salts of methylnaltrexone | WYETH, LLC (US) | 2013-09-03 | — | — | US | claimed |
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH LLC (US) | 2012-03-22 | — | — | US | claimed |
| EP-2371357-A1 | Oral formulations and lipophilic salts of methylnaltrexone | Wyeth LLC (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2011112816-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2046388-A2 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080070975-A1 | Formulations for parenteral delivery of compounds and uses thereof | WYETH (US) | 2008-03-20 | — | — | US | claimed |
| WO-2008019115-A2 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH (US) | 2008-02-14 | — | — | WO | claimed |
| US-6482517-B1 | Coated particles, methods of making and using | SELECT RELEASE, L.C. | 2002-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-10376505-B2 | Oral formulations and lipophilic salts of methylnaltrexone | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-20190117645-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-20220023200-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | TDP1 4777/4885EYA2 4419/4885APP 4547/4885 |
| US-20140249171-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-20230414490-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | TDP1 4777/4885EYA2 4419/4885APP 4547/4885 |
| US-20190117646-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-10357449-B2 | — | OPRL1, OPRK1, OPRM1 | TDP1 4212/4885EYA2 3821/4885APP 3790/4885 |
| US-20190314365-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-10307417-B2 | Oral formulations and lipophilic salts of methylnaltrexone | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-20130330407-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TDP1 4506/4885EYA2 4345/4885APP 3819/4885 |
| US-20080070975-A1 | Formulations for parenteral delivery of compounds and uses thereof | OPRL1, OPRK1, OPRM1 | TDP1 4777/4885EYA2 4419/4885APP 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.